Galderma to Buy ZO Skin Health for $1.5 Billion
By Aimee Look
Dermatology company Galderma agreed to buy ZO Skin Health from Blackstone and the Obagi family for $1.5 billion, including debt, in a move to grow its premium portfolio.
The Swiss company said Wednesday that it agreed to fully acquire ZO Skin Health from its shareholders, which include the Obagi family and funds managed by Blackstone Tactical Opportunities.
The transaction is expected to close in the current quarter or early 2027 and is subject to regulatory approvals, it said.
Galderma, which currently owns brands Alastin and Cetaphil, said the acquisition of California-based ZO Skin Health would help it serve healthcare professionals and patients.
ZO Skin Health, which has more than 40 products, would complement Galderma's Alastin brand in particular, the Swiss company said.
Write to Aimee Look at aimee.look@wsj.com
(END) Dow Jones Newswires
October 14, 2026 01:40 ET (05:40 GMT)
Copyright (c) 2026 Dow Jones & Company, Inc.The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.
Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.
Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.
Popular
The Smartest Moves for Bond Investors Today, and What to Do When You Have Too Many Investments
5 Stocks to Sell for Tax-Loss Harvesting
33 Undervalued Stocks to Buy Before the Market Shifts Again
Undervalued by 15%, This Utilities Stock Could Be an Unexpected AI Winner
United States